Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Issues

Volume 2, Issue 8
August 2022
Issue Cover
All Issues
EISSN 2767-9764
A Spatially Resolved Mechanistic Growth Law for Cancer Drug Development Predicting Tumor Growing Fractions
Adam Nasim; James Yates; Gianne Derks; Carina Dunlop
View articletitled, A Spatially Resolved Mechanistic Growth Law for Cancer Drug Development Predicting Tumor Growing Fractions
Supplementary data
Open the PDF for in another window
Classifying cGAS-STING Activity Links Chromosomal Instability with Immunotherapy Response in Metastatic Bladder Cancer
Mateo Sokač; Johanne Ahrenfeldt; Kevin Litchfield; Thomas B.K. Watkins; Michael Knudsen; Lars Dyrskjøt; Martin R. Jakobsen; Nicolai J. Birkbak
View articletitled, Classifying cGAS-STING Activity Links Chromosomal Instability with Immunotherapy Response in Metastatic Bladder Cancer
Supplementary data
Open the PDF for in another window
Suppressed Cellular Senescence Mediated by T-box3 in Aged Gastric Epithelial Cells may Contribute to Aging-related Carcinogenesis
Akio Takeuchi; Naoki Asano; Akira Imatani; Masashi Saito; Xiaoyi Jin; Masahiro Saito; Takeshi Kanno; Waku Hatta; Kaname Uno; Tomoyuki Koike; Atsushi Masamune
View articletitled, Suppressed Cellular Senescence Mediated by T-box3 in Aged Gastric Epithelial Cells may Contribute to Aging-related Carcinogenesis
Supplementary data
Open the PDF for in another window
GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors
Valentino Clemente; Asumi Hoshino; Mihir Shetty; Andrew Nelson; Britt K. Erickson; Ruth Baker; Nathan Rubin; Mahmoud Khalifa; S. John Weroha; Emil Lou; Martina Bazzaro
View articletitled, GLS1 is a Protective Factor in Patients with Ovarian Clear Cell Carcinoma and its Expression Does Not Correlate with ARID1A-mutated Tumors
Supplementary data
Open the PDF for in another window
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
Kristie A. Blum; Jeffrey G. Supko; Michael B. Maris; Ian W. Flinn; Andre Goy; Anas Younes; Suresh Bobba; Adrian M. Senderowicz; Sergey Efuni; Ronda Rippley; Gozde Colak; Patrick Trojer; Jeremy S. Abramson
View articletitled, A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
Supplementary data
Open the PDF for in another window
Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access
Marcus A. Florez; Jan O. Kemnade; Nan Chen; Wendy Du; Anita L. Sabichi; Daniel Y. Wang; Quillan Huang; Courtney N. Miller-Chism; Aparna Jotwani; Albert C. Chen; David Hernandez; Vlad C. Sandulache
View articletitled, Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access
Supplementary data
Open the PDF for in another window
Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge
Andre van der Westhuizen; Megan Lyle; Moira C. Graves; Xiaoqiang Zhu; Jason W. H. Wong; Kerrie Cornall; Shu Ren; Leanna Pugliese; Richard Levy; Adeeb Majid; Ricardo E. Vilain; Nikola A. Bowden
View articletitled, Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge
Supplementary data
Open the PDF for in another window
A TCR-like CAR Promotes Sensitive Antigen Recognition and Controlled T-cell Expansion Upon mRNA Vaccination
Matthias Birtel; Ralf-Holger Voss; Katharina Reinhard; Benjamin Rengstl; Yasmina Ouchan; Kristina Michel; Nina Hayduk; Bodo Tillmann; René Becker; Martin Suchan; Matthias Theobald; Petra Oehm; Özlem Türeci; Ugur Sahin
View articletitled, A TCR-like CAR Promotes Sensitive Antigen Recognition and Controlled T-cell Expansion Upon mRNA Vaccination
Supplementary data
Open the PDF for in another window
Na+/H+-exchanger 1 Enhances Antitumor Activity of Engineered NK-92 Natural Killer Cells
Yao-Yu Gong; Hongguang Shao; Yu Li; Patricia Brafford; Zachary E. Stine; Jing Sun; Dean W. Felsher; Jordan S. Orange; Steven M. Albelda; Chi V. Dang
View articletitled, Na<sup>+</sup>/H<sup>+</sup>-exchanger 1 Enhances Antitumor Activity of Engineered NK-92 Natural Killer Cells
Supplementary data
Open the PDF for in another window
Brain Neural Progenitors are New Predictive Biomarkers for Breast Cancer Hormonotherapy
Agnes Basseville; Chiara Cordier; Fadoua Ben Azzouz; Wilfried Gouraud; Hamza Lasla; Fabien Panloup; Mario Campone; Pascal Jézéquel
View articletitled, Brain Neural Progenitors are New Predictive Biomarkers for Breast Cancer Hormonotherapy
Supplementary data
Open the PDF for in another window
Ribonuclease H2 Subunit A Preserves Genomic Integrity and Promotes Prostate Cancer Progression
Naoki Kimura; Ken-ichi Takayama; Yuta Yamada; Haruki Kume; Tetsuya Fujimura; Satoshi Inoue
View articletitled, Ribonuclease H2 Subunit A Preserves Genomic Integrity and Promotes Prostate Cancer Progression
Supplementary data
Open the PDF for in another window
Patients with Lung Cancer of Different Racial Backgrounds Harbor Distinct Immune Cell Profiles
Yitian Xu; Licheng Zhang; Jose Thaiparambil; Sunny Mai; Dimuthu Nuwan Perera; Jilu Zhang; Ping-Ying Pan; Cristian Coarfa; Kenneth Ramos; Shu-Hsia Chen; Randa El-Zein
View articletitled, Patients with Lung Cancer of Different Racial Backgrounds Harbor Distinct Immune Cell Profiles
Supplementary data
Open the PDF for in another window
Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer
Joel R. Eisner; Kirk D. Beebe; Gregory M. Mayhew; Yoichiro Shibata; Yuelong Guo; Carol Farhangfar; Farhang Farhangfar; Joshua M. Uronis; Jill Mooney; Michael V. Milburn; David Foureau; Richard L. White; Asim Amin; Marcos E. Milla
View articletitled, Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer
Supplementary data
Open the PDF for in another window
Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma
Robert H.I. Andtbacka; Yan Wang; Robert H. Pierce; Jean S. Campbell; Melinda Yushak; Mohammed Milhem; Merrick Ross; Katie Niland; Robert D. Arbeit; Sudha Parasuraman; Kris Bickley; Cecilia CS Yeung; Lauri D. Aicher; Kimberly S. Smythe; Lu Gan
View articletitled, Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma
Supplementary data
Open the PDF for in another window

Advertisement

Email alerts

eTOC Alert
Close Modal
Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies
Peritumoral Immune-suppressive Mechanisms Impede Intratumoral Lymphocyte Infiltration into Colorectal Cancer Liver versus Lung Metastases
Multifactorial Remodeling of the Cancer Immunopeptidome by IFNγ
  • Online ISSN 2767-9764

AACR Journals

 

 

  • Copyright © 2023 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept